Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after several negative developments weighed on the sector. Weakness in managed care ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

Two weeks after Supernus unveiled the Sage Therapeutics acquisition, all 338 employees from the struggling biotech are being laid off.

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the ...

Exchange Traded Concepts LLC increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.5% during the first quarter, HoldingsChannel reports. The firm owned 24,881 ...

Sage Therapeutics accepts $795M buyout from Supernus Pharmaceuticals, surpassing Biogen's offer. Deal adds Zurzuvae to Supernus' portfolio.

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus’ leading presence in neuropsychiatric ...

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported a loss of $11.8 million in its first quarter. The Rockville, Maryland-based company said it ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported a loss of $11.8 million in its first quarter. The Rockville, Maryland-based company said it ...